One way to measure progress in fighting AIDS is to compare the number of new HIV infections with the increase in HIV positive people on antiretroviral therapy (ART) over a given time period. An AIDS epidemic reaches its “tipping point” when the number of annual new HIV infection falls below the annual increase in patients starting ART. This poster was presented at the 2014 HIV Research for Prevention Conference in South Africa.
The Tipping Point: Moving From Rhetoric to Real Milestones for Ending AIDS
HIV Cure Research – An introductory fact sheet
This introductory 2-page document defines cure, reviews the scientific evidence to date, and outlines key research strategies currently being pursued. This fact sheet is part of a series on emerging HIV prevention strategies.
Px Wire July-September 2014, Vol. 7, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue comes out on the eve of the International AIDS Conference in Melbourne, Australia—and we begin with “AVAC’s Take” on key messages and commitments to look for at and after the meeting. We also call for more PrEP demonstration projects and provide an update of the proposed ECHO trial.
Px Wire October-December 2014, Vol. 7, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue, we offer a selective “state of the union” update on various areas of the prevention field—highlighting key developments, messages and areas of work that warrant particular joint attention at the first HIV Research for Prevention (HIV R4P) conference and beyond.
PrEP for Black Gay and Bi-sexual Men in the US: What you need to know
This factsheet includes information on accessing and paying for PrEP, side effects and outlines key information on the relevance of PrEP for Black gay and bisexual men.
Good Participatory Practice: Guidelines for TB Drug Trials
The Good Participatory Practice (GPP) guidelines for TB Drug Trials is the product of a collaboration between AVAC and the Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens. The guidelines offer trial funders, sponsors, and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle. This first edition, published in 2012, contains five sections that provide context, foundational principles, and key practices for conducting TB drug trials.
GPP Overview PowerPoint
The GPP Overview PowerPoint contains 35 slides that users can draw from when introducing the Good Participatory Practice guidelines. The PowerPoint contains slides on the history and content of the guidelines, who the intended user is, the role and importance of GPP in the field and strategies for effective use. The slide deck is broken into sections allowing slides can be rearranged or deleted to make a complete presentation.
Pre-Exposure Prophylaxis: An introductory factsheet
This introductory 2-page document defines PrEP, reviews the scientific evidence to date, and outlines key research, regulatory and advocacy issues going forward. This factsheet is part of a series on emerging HIV prevention strategies.
Treatment as Prevention: An introductory factsheet
This introductory 2-page document defines treatment as prevention, reviews the scientific evidence behind it, and outlines implementation advocacy priorities. The factsheet is part of a series on emerging HIV prevention strategies.
Microbicides for HIV Prevention: An introductory factsheet
This introductory 2-page document defines microbicides and reviews the state of research on some leading candidates.